Amalgamated Bank Buys 227 Shares of Revvity Inc. (NYSE:RVTY)

Amalgamated Bank boosted its stake in shares of Revvity Inc. (NYSE:RVTY) by 1.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,777 shares of the company’s stock after purchasing an additional 227 shares during the period. Amalgamated Bank’s holdings in Revvity were worth $2,516,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Jones Financial Companies Lllp raised its stake in shares of Revvity by 39.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,312 shares of the company’s stock worth $481,000 after buying an additional 1,228 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Revvity by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 843,145 shares of the company’s stock worth $94,103,000 after acquiring an additional 12,657 shares in the last quarter. Victory Capital Management Inc. raised its stake in Revvity by 17.4% during the 4th quarter. Victory Capital Management Inc. now owns 70,250 shares of the company’s stock worth $7,841,000 after acquiring an additional 10,390 shares during the period. Assetmark Inc. lifted its holdings in Revvity by 3,700.0% during the fourth quarter. Assetmark Inc. now owns 266 shares of the company’s stock valued at $30,000 after purchasing an additional 259 shares in the last quarter. Finally, Proficio Capital Partners LLC lifted its holdings in Revvity by 12,298.3% during the fourth quarter. Proficio Capital Partners LLC now owns 195,769 shares of the company’s stock valued at $21,850,000 after purchasing an additional 194,190 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Performance

NYSE RVTY opened at $101.31 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.58 and a quick ratio of 2.99. Revvity Inc. has a 1-year low of $87.70 and a 1-year high of $129.50. The business has a 50 day simple moving average of $94.04 and a two-hundred day simple moving average of $104.87. The stock has a market capitalization of $11.94 billion, a PE ratio of 43.11, a P/E/G ratio of 2.56 and a beta of 0.98.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.05. Revvity had a net margin of 10.35% and a return on equity of 7.73%. The firm had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. During the same period last year, the firm posted $0.98 earnings per share. Revvity’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, research analysts predict that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be issued a $0.07 dividend. The ex-dividend date is Friday, July 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. Revvity’s dividend payout ratio (DPR) is presently 11.91%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on RVTY shares. JPMorgan Chase & Co. reduced their price objective on shares of Revvity from $120.00 to $100.00 and set a “neutral” rating for the company in a research note on Tuesday, April 29th. Raymond James Financial reissued an “outperform” rating and set a $120.00 price target (down from $145.00) on shares of Revvity in a report on Tuesday, April 29th. Bank of America lowered their price objective on Revvity from $116.00 to $110.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Wells Fargo & Company cut their target price on Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Finally, The Goldman Sachs Group decreased their target price on Revvity from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $123.64.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.